The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Open accessAbstract
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
Bermejo-Martin, J. F., Ortiz de Lejarazu, R., Pumarola, T., Rello, J., Almansa, R., Ramírez, P., Martin-Loeches, I., Varillas, D., Gallegos, M. C., Serón, C., et al. (2009) · Critical Care · doi:10.1186/cc8208 · Cited by 373
Josset, L., Menachery, V. D., Gralinski, L. E., Agnihothram, S., Sova, P., Carter, V. S., Yount, B. L., Graham, R. L., Baric, R. S., & Katze, M. G. (2013) · mBio · doi:10.1128/mbio.00165-13 · Cited by 293
Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Faure, E., Poissy, J., Goffard, A., Fournier, C., Kipnis, E., Titecat, M., Bortolotti, P., Martinez, L., Dubucquoi, S., Dessein, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088716 · Cited by 248
Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS)
Tse, G. M.-K., To, K.-F., Chan, P. K.-S., Lo, A. W. I., Ng, K.-C., Wu, A., Lee, N., Wong, H.-C., Mak, S.-M., Chan, K.-F., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.013276 · Cited by 238
IL-17 response mediates acute lung injury induced by the 2009 Pandemic Influenza A (H1N1) Virus
Li, C., Yang, P., Sun, Y., Li, T., Wang, C., Wang, Z., Zou, Z., Yan, Y., Wang, W., Wang, C., et al. (2012) · Cell Research · doi:10.1038/cr.2011.165 · Cited by 168
Dual Roles of IL-27 in Cancer Biology and Immunotherapy
Fabbi, M., Carbotti, G., & Ferrini, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/3958069 · Cited by 142
IL-22: There Is a Gap in Our Knowledge
Zenewicz, L. A. (2018) · ImmunoHorizons · doi:10.4049/immunohorizons.1800006 · Cited by 107
Bright, J. J., Du, C., & Sriram, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.6255 · Cited by 87
Cited by
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
Barnes, B. J., Adrover, J. M., Baxter-Stoltzfus, A., Borczuk, A., Cools-Lartigue, J., Crawford, J. M., Daßler-Plenker, J., Guerci, P., Huynh, C., Knight, J. S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200652 · Cited by 1,486
SARS-CoV-2 infection: The role of cytokines in COVID-19 disease
Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, J. M., Ruiz, C., & Melguizo-Rodríguez, L. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.001 · Cited by 1,121
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Aging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007
Metadata
- Authors
- Wu, D., & Yang, X. O.
- Venue
- Journal of Microbiology, Immunology and Infection
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 53
- Issue
- 3
- Pages
- 368-370
- ISSN
- 1684-1182 (ISSN-L)
- OpenAlex
- W3012515447
- Cited by
- 785
- References
- 10
- FWCI
- 21.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. https://app.cochat.ai/papers/10.1016/j.jmii.2020.03.005
- The paper
- Wu, D., & Yang, X. O. (2020). TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of Microbiology, Immunology and Infection. https://doi.org/10.1016/j.jmii.2020.03.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.